Aspen Neuroscience, Inc. · NASDAQ Global Select · priced Oct 30, 2026 · $141M raised · $50M–$250M
Price since listing
- Hype
- Distribution
- Lock-up window
- Valley
- Accumulation
- Recovery
Volume bars are coloured by lifecycle phase. Markers: lock-up and early release (orange), earnings releases (E), follow-on offerings (F), research signals (rule id and signal; arrow up = buy signal, arrow down = sell or short signal, or sell signal for deals under $50M). Current phase: Hype.
Performance since the IPO
- ASPE
- S&P 500 (SPY)
- Typical IPO $50m–$250m
- Middle 50% of those IPOs
ASPE measured from its offer price; S&P 500 from the first trading day. The typical-IPO line is the median of 453 $50m–$250m IPOs from 2014–2025, by trading day.
Company
Aspen Neuroscience, Inc. develops autologous induced pluripotent stem cell (iPSC)-derived cell replacement therapies for neurodegenerative diseases. The company's develops ANPD001, an investigational single-dose, autologous dopaminergic neuronal precursor cell (DANPC) therapy for Parkinson's disease. It operates in the United States. The company also advances additional cell replacement candidates targeting both spor…
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Employees
- 120
- Market cap
- $401M
- Website
- www.aspenneuroscience.com
Returns vs offer, compared with 92 IPOs $50m–$250m
| Horizon | ASPE | Peer median | Peers below offer |
|---|---|---|---|
| Day 1 | -0.7% | +0.2% | 37% n=92 |
| Day 20 | – | +0.3% | 46% n=87 |
| Day 60 | – | +3.1% | 44% n=84 |
| Day 120 | – | -6.9% | 58% n=73 |
| Day 180 | – | -13.1% | 56% n=64 |
Research signals
No rule has triggered for this IPO.
Signals from Oct 29, 2026 onward are recorded live; earlier ones show what the rules would have flagged at the time. See methodology.
See the track record for every live signal and its result.
Research signals only, not investment advice. Lock-up terms come from prospectuses; prices from Yahoo Finance and may be delayed or wrong.